---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-137041"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:20:38.636919+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration

## Summary
- CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.
- Consulting agreements are one-year, hourly compensation; executives retain their roles and responsibilities.
- Separation agreements provide full acceleration of all outstanding equity awards, vested immediately on June 5, 2025.
- Extended post-Transition exercise period to earlier of Change of Control or 180 days after separation.
- Transition part of previously announced process to explore strategic alternatives and extend capital resources.

## SEC filing metadata
- accession: 0001193125-25-137041
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312525137041/0001193125-25-137041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312525137041/d17737d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-137041
- JSON: https://secwatch.observer/filing/0001193125-25-137041.json
- Plain text: https://secwatch.observer/filing/0001193125-25-137041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.